1. Academic Validation
  2. Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity

Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity

  • Bioorg Med Chem Lett. 2019 Mar 15;29(6):839-843. doi: 10.1016/j.bmcl.2019.01.016.
Seung Cheol Baek 1 Myung-Gyun Kang 2 Ji-Eun Park 3 Jae Pil Lee 1 Hanna Lee 3 Hyung Won Ryu 4 Chul Min Park 5 Daeui Park 6 Myoung-Lae Cho 3 Sei-Ryang Oh 4 Hoon Kim 7
Affiliations

Affiliations

  • 1 Department of Pharmacy and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea.
  • 2 Department of Predictive Toxicology, Korea Institute of Toxicology, Daejeon 34114, Republic of Korea.
  • 3 National Development Institute of Korean Medicine, Gyeongsan 38540, Republic of Korea.
  • 4 Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongju, Chungbuk 28116, Republic of Korea.
  • 5 Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
  • 6 Department of Predictive Toxicology, Korea Institute of Toxicology, Daejeon 34114, Republic of Korea; Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
  • 7 Department of Pharmacy and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea. Electronic address: [email protected].
Abstract

Osthenol (6), a prenylated coumarin isolated from the dried roots of Angelica pubescens, potently and selectively inhibited recombinant human monoamine oxidase-A (hMAO-A) with an IC50 value of 0.74 µM and showed a high selectivity index (SI > 81.1) for hMAO-A versus hMAO-B. Compound 6 was a reversible competitive hMAO-A inhibitor (Ki = 0.26 µM) with a potency greater than toloxatone (IC50 = 0.93 µM), a marketed drug. Isopsoralen (3) and bakuchicin (1), furanocoumarin derivatives isolated from Psoralea corylifolia L., showed slightly higher IC50 values (0.88 and 1.78 µM, respectively) for hMAO-A than 6, but had low SI values (3.1 for both). Other Coumarins tested did not effectively inhibit hMAO-A or hMAO-B. A structural comparison suggested that the 8-(3,3-dimethylallyl) group of 6 increased its inhibitory activity against hMAO-A compared with the 6-methoxy group of scopoletin (4). Molecular docking simulations revealed that the binding affinity of 6 for hMAO-A (-8.5 kcal/mol) was greater than that for hMAO-B (-5.6 kcal/mol) and that of 4 for hMAO-A (-7.3 kcal/mol). Docking simulations also implied that 6 interacted with hMAO-A at Phe208 and with hMAO-B at Ile199 by carbon hydrogen bondings. Our findings suggest that osthenol, derived from Natural Products, is a selective and potent reversible inhibitor of MAO-A, and can be regarded a potential lead compound for the design of novel reversible MAO-A inhibitors.

Keywords

Human monoamine oxidase A; Molecular docking; Osthenol; Selective competitive inhibitor.

Figures
Products